South Korea-based JW Pharmaceutical (JWP) has entered into a global licensing agreement with LEO Pharma whereby the former will grant the latter's exclusive rights to develop and commercialize its atopic dermatitis drug JW1601 in a deal that could reach KRW450bn ($402m).
bluebird bio and Gritstone Oncology have partnered to research, develop and commercialize products for the treatment of cancer using cell therapy.
ApoGen Biotechnologies, a biotechnology firm engaged in the development of a new class of therapeutics targeting drivers of cancer genomic mutations, has expanded its series A financing to a total of $11m.
The Centre for the Commercialization of Antibodies and Biologics (CCAB) has agreed to provide a new investment to help advance ImmunoBiochem’s novel breast cancer therapeutic candidate one step closer to the clinic.
Harbour BioMed and Sichuan Kelun-Biotech Biopharmaceutical (Kelun-Biotech) have entered into a partnership to develop and commercialize the latter’s A167, an anti-PD-L1 antibody, for the treatment of cancer.
AbbVie has entered into clinical research collaboration with Tolero Pharmaceuticals to assess the potential benefits of venetoclax and alvocidib combination in relapsed/refractory acute myeloid leukemia (AML).
WuXi AppTec ‘s research service division and Cyclica have announced a multi-phase collaboration to advance drug discovery programs by driving insights into small molecule polypharmacology, while further evolving Cyclica’s biophysics and AI-augmented platform.
Biotechnology firm BioNTech has collaborated with Pfizer for the development of mRNA-based vaccines to prevent influenza (flu).
Haplogen and German pharma firm Bayer have entered into a collaboration to develop drug candidates for the treatment of chronic obstructive pulmonary disease (COPD) and other pulmonary diseases.
Orchard Therapeutics, a biotechnology company focused on developing gene therapies for rare diseases, has raised $150m through a Series C funding round.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.